NSB 2.70% 3.8¢ neuroscientific biopharmaceuticals ltd

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

  1. 1,049 Posts.
    lightbulb Created with Sketch. 858
    tend to disagree,did you read the quarterly as its on track for testing glaucoma,with r+d refund 5 mil in the bank more than the market cap.
    NSB is working with a highly experienced and qualified regulatory consultancy that holds
    offices in UK, EU, US and Australia, to ensure that NSB can gain as much insight from the FDA
    and confirm that the development plan in place for EmtinB within Ophthalmology is within
    the regulator's expectations to allow the initiation of a clinical trial.
    It is expected that this submission will occur in Q1 2024.

    Currently a buy for me again
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
(20min delay)
Last
3.8¢
Change
0.001(2.70%)
Mkt cap ! $5.494M
Open High Low Value Volume
3.8¢ 3.8¢ 3.8¢ $32 845

Buyers (Bids)

No. Vol. Price($)
2 63773 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 233956 2
View Market Depth
Last trade - 10.06am 08/07/2024 (20 minute delay) ?
NSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.